Since statins have reported benefits in cardiovascular outcome in COVID-19 patients11,12 and statins are potent pharmacological activators of KLF2,13,14 we postulated that KLF2 activation by statins could counteract COVID-19-associated endothelial dysfunction. The gene discussed is KLF2; the disease is endothelial dysfunction.